Published in Cleve Clin J Med on April 01, 2011
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study (GeCCO) | NCT00995514
Pharmacogenetics: Using Genetic Information to Guide Drug Therapy. Am Fam Physician (2015) 1.39
Program in pharmacogenomics at the Ohio State University Medical Center. Pharmacogenomics (2012) 1.07
Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med (2011) 0.94
Deciphering next-generation pharmacogenomics: an information technology perspective. Open Biol (2014) 0.91
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug Metabol Drug Interact (2013) 0.81
CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. Eur J Clin Pharmacol (2012) 0.80
Documenting Pharmacogenomic Testing with CPT Codes. J AHIMA (2016) 0.79
SNARE complex in developmental psychiatry: neurotransmitter exocytosis and beyond. J Neural Transm (Vienna) (2016) 0.78
Stroke Genetics Update: 2011. Curr Cardiovasc Risk Rep (2011) 0.78
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Rev Cardiovasc Ther (2013) 0.76
Prevalence of clinically actionable genotypes and medication exposure of older adults in the community. Pharmgenomics Pers Med (2017) 0.75
Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany. Adv Ther (2016) 0.75
Clinically relevant pharmacogenomic testing in pediatric practice. Clin Pediatr (Phila) (2014) 0.75
Pharmacogenomics for the primary care provider: why should we care? Cleve Clin J Med (2011) 0.75
Comparative effectiveness of quetiapine and haloperidol in delirium: A single blind randomized controlled study. World J Psychiatry (2016) 0.75
Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS (2016) 0.75
Gene-based, rational drug-dosing: An evolving, complex opportunity. Cleve Clin J Med (2011) 0.75
Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol (2017) 0.75
Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature. Front Public Health (2016) 0.75
Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis (2017) 0.75
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 32.05
Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1997) 13.66
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med (2007) 5.39
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol (2010) 5.07
Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) (2001) 4.88
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther (2007) 4.33
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet (2006) 3.72
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics (2002) 3.45
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med (2009) 3.44
The incidence of adverse drug events in two large academic long-term care facilities. Am J Med (2005) 3.43
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics (1996) 3.02
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 2.98
Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry (2003) 2.71
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci (2001) 2.54
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J (2010) 2.43
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry (2008) 2.35
Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol (2009) 2.33
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry (2006) 2.29
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med (2005) 2.06
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther (2004) 1.90
The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care (2005) 1.68
No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol (2004) 1.55
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J (2006) 1.53
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther (2007) 1.42
Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA (2001) 1.41
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther (2008) 1.40
Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2009) 1.38
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther (2006) 1.33
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics (2005) 1.32
Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther (2009) 1.31
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J (2009) 1.28
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther (2006) 1.16
DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr (2009) 1.15
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res (2009) 1.14
CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci (2007) 1.09
Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J (2009) 1.06
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol (2003) 1.03
Pharmacogenomics of antidepressant drugs. Pharmacol Ther (2009) 1.01
New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis (2007) 1.01
CYP2D6 genotyping and the pharmacogenetics of tamoxifen. Clin Adv Hematol Oncol (2008) 0.97
The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther (1996) 0.97
Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med (2003) 0.97
Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol (2006) 0.97
Costs of intravenous adverse drug events in academic and nonacademic intensive care units. Med Care (2008) 0.97
Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA (2009) 0.96
Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug Metab Rev (2008) 0.95
Warfarin pharmacogenomics: a big step forward for individualized medicine: enlightened dosing of warfarin. Eur J Hum Genet (2008) 0.95
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit (2008) 0.95
Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc (2007) 0.94
Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry (2003) 0.93
CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther (2008) 0.91
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med (2008) 0.89
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Netw (2009) 0.87
Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol (2009) 0.84
The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J Affect Disord (2008) 0.83
The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci (2006) 0.82
CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry (2006) 0.80
Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol (2005) 0.78
[Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype]. Psychiatr Pol (2003) 0.78
Strategies and methods for research on sex differences in brain and behavior. Endocrinology (2004) 5.02
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol (2011) 2.59
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol (2009) 2.34
Innate immune gene polymorphisms in tuberculosis. Infect Immun (2012) 1.89
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma (2009) 1.58
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res (2013) 1.51
miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51
The human zinc transporter SLC39A8 (Zip8) is critical in zinc-mediated cytoprotection in lung epithelia. Am J Physiol Lung Cell Mol Physiol (2008) 1.45
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics (2007) 1.40
Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain (2008) 1.37
Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry (2004) 1.33
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol (2006) 1.31
Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology (2010) 1.29
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol Ther (2004) 1.26
Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS One (2010) 1.24
Nicotinic α5 receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms. Eur J Hum Genet (2010) 1.23
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One (2012) 1.21
Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol (2010) 1.20
Genetically determined interaction between the dopamine transporter and the D2 receptor on prefronto-striatal activity and volume in humans. J Neurosci (2009) 1.18
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica (2010) 1.17
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther (2007) 1.16
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet (2013) 1.16
Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov (2006) 1.15
Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology (2011) 1.13
Functional variation of the dopamine D2 receptor gene is associated with emotional control as well as brain activity and connectivity during emotion processing in humans. J Neurosci (2009) 1.11
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J (2011) 1.11
Allele-specific tumor spectrum in pten knockin mice. Proc Natl Acad Sci U S A (2010) 1.08
Program in pharmacogenomics at the Ohio State University Medical Center. Pharmacogenomics (2012) 1.07
Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in Psychopharmacology 232, 305-314, 2014. Psychopharmacology (Berl) (2015) 1.05
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res (2009) 1.04
Whole transcriptome RNA-Seq allelic expression in human brain. BMC Genomics (2013) 0.99
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica (2012) 0.99
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit (2008) 0.98
Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet Genomics (2011) 0.97
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs (2010) 0.96
Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J (2011) 0.95
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res (2013) 0.94
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet (2009) 0.94
Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene. PLoS One (2009) 0.93
Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorg Med Chem (2006) 0.91
Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry. Anal Chem (2004) 0.90
mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol Pharmacol (2012) 0.89
Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc-. J Med Chem (2007) 0.88
Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics (2008) 0.88
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. Am J Hematol (2013) 0.87
Involvement of endocytic organelles in the subcellular trafficking and localization of riboflavin. J Pharmacol Exp Ther (2003) 0.86
Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res (2012) 0.86
5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochem Biophys Res Commun (2006) 0.86
Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Antimicrob Agents Chemother (2003) 0.86
Modeling of active transport systems. Adv Drug Deliv Rev (2002) 0.86
Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol Psychiatry (2012) 0.86
A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol (2013) 0.84
A novel liposomal formulation of flavopiridol. Int J Pharm (2008) 0.84
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Invest New Drugs (2012) 0.84
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. J Pharm Biomed Anal (2013) 0.81
A pharmacoproteomics study of the cancer cell line EKVX using capillary-LC/MS/MS. Mol Pharm (2006) 0.81
Transporter and ion channel gene expression after Caco-2 cell differentiation using 2 different microarray technologies. AAPS J (2004) 0.81
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug Metabol Drug Interact (2013) 0.81
Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms: reduced expression associated with rs247616. Pharmacogenet Genomics (2015) 0.80
Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses. Am J Vet Res (2012) 0.80
Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J (2012) 0.80
Intracellular processing of riboflavin in human breast cancer cells. Mol Pharm (2008) 0.80
6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. Pain Med (2011) 0.80
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma (2013) 0.80
Regulatory polymorphisms in key candidate genes for disease susceptibility and drug response: a mandate for valid genetic biomarkers. Expert Rev Mol Diagn (2010) 0.79
Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes. Nanomedicine (2012) 0.79
Association study of the estrogen receptor gene ESR1 with postpartum depression--a pilot study. Arch Womens Ment Health (2013) 0.79
Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver. Pharmacogenet Genomics (2013) 0.79
Recognition, co-internalization, and recycling of an avian riboflavin carrier protein in human placental trophoblasts. J Pharmacol Exp Ther (2006) 0.79
Synaptic signaling and aberrant RNA splicing in autism spectrum disorders. Front Synaptic Neurosci (2011) 0.78
Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait loci (eQTLs). BMC Genomics (2015) 0.78
Family-based clinical associations and functional characterization of the serotonin 2A receptor gene (HTR2A) in autism spectrum disorder. Autism Res (2014) 0.78
Regulatory polymorphisms in CYP2C19 affecting hepatic expression. Drug Metabol Drug Interact (2013) 0.78
Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. Pharmacogenet Genomics (2016) 0.77
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet (2013) 0.77
Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.76
CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenet Genomics (2016) 0.76
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.76
Inhibitors of tubulin assembly identified through screening a compound library. Chem Biol Drug Des (2008) 0.76
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). Am J Hematol (2015) 0.75
Allelic mRNA expression of sortilin-1 (SORL1) mRNA in Alzheimer's autopsy brain tissues. Neurosci Lett (2008) 0.75
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet (2017) 0.75
Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. J Cardiovasc Pharmacol (2015) 0.75
Analysis of the transport of and cytotoxic effects for nalbuphine solution in corneal cells. Am J Vet Res (2012) 0.75
Conference Scene: Lessons learned from the 5th Statistical Analysis Workshop of the Pharmacogenetics Research Network. Pharmacogenomics (2010) 0.75
Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses. Am J Vet Res (2012) 0.75
Acetaminophen pediatric dose selection: caregiver satisfaction regarding the antipyretic efficacy of acetaminophen in children. Clin Pediatr (Phila) (2012) 0.75